Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XMT 1660

Drug Profile

XMT 1660

Alternative Names: B7-H4 ADC - Mersana Therapeutics; B7-H4 targeting antibody drug conjugate - Mersana Therapeutics; XMT-1660

Latest Information Update: 28 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mersana Therapeutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Triple negative breast cancer

Most Recent Events

  • 27 Mar 2023 Mersana Therapeutics has several patents pending for XMT 1660 in USA and European Union
  • 12 Sep 2022 XMT 1660 receives Fast Track designation for Triple-negative-breast cancer [IV] (Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in USA
  • 15 Aug 2022 Phase-I clinical trials in Endometrial cancer (Late-stage disease, Monotherapy, Metastatic disease, Second-line therapy or greater, Recurrent) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top